A systematic computational analysis of pharmacological options in neuroinflammatory-induced autism spectrum disorder in children: A potential for drug repositioning.

Abstract

Background: Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by deficits in social communication and the presence of restricted or repetitive behaviors. Although its underlying pathophysiological mechanisms remain unclear, growing evidence indicates that neuroinflammation plays a significant role, especially in children.

Objective: This study aims to explore neuroinflammatory pathways in children aged 12 and under, with a focus on potential therapeutic opportunities through drug repositioning.

Methods: We conducted a systematic computational analysis using data from 27 studies and bioinformatics resources such as DrugBank and PubChem, identifying over 8,000 potential drug candidates from the initial 29 treatments retrieved from the literature.

Results: Key compounds such as cannabidiol, fluoxetine, and risperidone were highlighted for their broad therapeutic potential. In addition, emerging treatments, including cell-based therapies and dietary interventions, were explored.

Conclusion: Our findings support drug repositioning as an effective strategy for developing new ASD treatments during critical developmental periods, emphasizing the need for further research to validate these pathways and the efficacy of innovative therapies.